The Manila Times

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug ...
TipRanks on MSN

Daiichi Sankyo’s Latest Clinical Study: A Potential Game-Changer in Esophageal Cancer Treatment

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The study titled A Phase 1/2 Open-Label, ...
Targeted Oncology

Nivolumab/Ipilimumab Combo Shows Long-Term PFS Benefit in MSI-H mCRC

Ipilimumab plus nivolumab improved PFS over nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns. The combination showed higher overall response rates and a favorable safety profile ...
The Manila Times

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...